With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25637-16-5,4-Bromotetrahydropyran,as a common compound, the synthetic route is as follows.
Cesium carbonate (450 mg, 1.4 mmol) was added to a solution of N-(4-((7-hydroxy-6-methoxyquinazolin-4-yl)oxy)phenyl)-2-( 4-isopropyl-1H-1 ,2,3-triazol-1-yl)acetamide (20010 mg, 0.5 mmol) and 4-bromotetrahydro-2H-pyran (456 mg, 2.8 mmol) in DMF (3 mL) undernitrogen. The resulting mixture was stirred at 100C for 3 hours. The crude product waspurified by preparative HPLC. Fractions containing the desired product were combined andconcentrated under vacuum to afford the title compound as a white solid (124 mg, 52%). 1HNMR (400 MHz, DMSO-d6) 8 1.26 (6H, d), 1.61 – 1.75 (2H, m), 2.09 (2H, d), 2.95 – 3.0715 (lH, m), 3.57- 3.59 (2H, m), 3.86- 3.95 (2H, m), 3.98 (3H, s), 4.94- 4.96 (lH, m), 5.30 (2H,s), 7.25-7.33 (2H, m), 7.55 (2H, d), 7.64- 7.73 (2H, m), 7.90 (lH, d), 8.54 (lH, s), 10.59 (lH,s); m/z: ES+ [M+H]+ 519.
25637-16-5, As the paragraph descriping shows that 25637-16-5 is playing an increasingly important role.
Reference£º
Patent; ASTRAZENECA AB; GRECU, Tudor; KETTLE, Jason, Grant; PACKER, Martin, John; PEARSON, Stuart, Eric; SMITH, James, Michael; (58 pag.)WO2018/197643; (2018); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics